T98GHomo sapiens (Human)Cancer cell line
Also known as: T98-G, T98 G, T-98G, T 98 G
Quick Overview
Human glioblastoma cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0556 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Brain[UBERON:UBERON_0000955] |
Donor Information
| Age | 61 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Glioblastoma |
|---|---|
| Lineage | CNS/Brain |
| Subtype | Glioblastoma |
| OncoTree Code | GB |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000571_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Met237Ile (c.711G>T) | Unspecified | - | from parent cell line T98G |
| MutationSimple | PTEN | p.Leu42Arg (c.125T>G) | Unspecified | - | from parent cell line T98G |
| MutationUnexplicit | PARD3 | Ex3-20del | Homozygous | - | from parent cell line T98G |
| MutationNone reported | IDH1 | - | - | - | PubMed=19435942 |
| Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
RNA sequencing data of different grade astrocytoma cell lines.";
Silva W.A., Valente V.
Data Brief 34:106643.1-106643.13(2021).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characteristics of A172 and T98G cell lines.";
Samoylovich M.P.
Tsitologiia 58:349-355(2016).
Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing.
Hill V.K., Kim J.-S., James C.D., Waldman T.
PLoS ONE 12:E0176683-E0176683(2017).
Human leukocyte antigen (HLA) peptides derived from tumor antigens induced by inhibition of DNA methylation for development of drug-facilitated immunotherapy.
Shraibman B., Kadosh D.M., Barnea E., Admon A.
Mol. Cell. Proteomics 15:3058-3070(2016).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing.
Patil V., Pal J., Somasundaram K.
Oncotarget 6:43452-43471(2015).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
A mass spectrometric-derived cell surface protein atlas.";
Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.
PLoS ONE 10:E0121314-E0121314(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
DNA fingerprinting of glioma cell lines and considerations on similarity measurements.
Hamou M.-F., Delorenzi M., Hegi M.E.
Neuro-oncol. 14:701-711(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.
Nakabayashi H., Yawata T., Shimizu K.
BMC Cancer 10:339.1-339.9(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.
Jones D.T.W., Collins V.P.
Neuro-oncol. 11:341-347(2009).
Hypoxia induces expression of a GPI-anchorless splice variant of the prion protein.
Yamazaki T., Tanamoto K.-i., Matsuda H., Sawada J.-i., Takatori K.
FEBS J. 275:2965-2976(2008).
Mechanisms of resistance of human glioma cells to Apo2 ligand/TNF-related apoptosis-inducing ligand.
Rieger J., Frank B., Weller M., Wick W.
Cell. Physiol. Biochem. 20:23-34(2007).
Overexpressed Skp2 within 5p amplification detected by array-based comparative genomic hybridization is associated with poor prognosis of glioblastomas.
Aoyagi M., Ohno K., Imoto I., Inazawa J.
Cancer Sci. 96:676-683(2005).
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Wang Y.-L., Zhu S.-J., Cloughesy T.F., Liau L.M., Mischel P.S.
Oncogene 23:1283-1290(2004).
P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.
Bahr O., Rieger J., Duffner F., Meyermann R., Weller M., Wick W.
Brain Pathol. 13:482-494(2003).
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death.
Wischhusen J., Naumann U., Ohgaki H., Rastinejad F., Weller M.
Oncogene 22:8233-8245(2003).
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
Wolf E., Gabius H.-J.
J. Cancer Res. Clin. Oncol. 127:375-386(2001).
Mutational profile of the PTEN gene in primary human astrocytic tumors and cultivated xenografts.
Collins V.P.
J. Neuropathol. Exp. Neurol. 58:1170-1183(1999).
Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines.
Van Meir E.G.
Brain Pathol. 9:469-479(1999).
Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses.
Krajewski S., Reed J.C., von Deimling A., Dichgans J.
Int. J. Cancer 79:640-644(1998).
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Frye C., Hu R., Swedlund B., Teng D.H.-F., Tavtigian S.V.
Nat. Genet. 15:356-362(1997).
Genetic analysis of indefinite division in human cells: identification of four complementation groups.
Pereira-Smith O.M., Smith J.R.
Proc. Natl. Acad. Sci. U.S.A. 85:6042-6046(1988).
T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro.
Stein G.H.
J. Cell. Physiol. 99:43-54(1979).
Brain tumors.";
Ali-Osman F.
(In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999).